Quantum Leap Healthcare Collaborative™ and G1 Therapeutics announced a collaboration to evaluate trilaciclib, an investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy, in a new randomized ...
Quantum Leap Healthcare Collaborative (QLHC) announced that a new randomized, investigational treatment arm for the I-SPY 2 TRIAL includes the study of olaparib and durvalumab, two agents from AstraZeneca.